Featured Research

from universities, journals, and other organizations

New medications faster: Harvesting biomolecules more quickly and reliably

Date:
April 11, 2010
Source:
Fraunhofer-Gesellschaft
Summary:
Before a new medication arrives on the market, it must be tested on animal models and in humans. In order to conduct these tests, a substantial amount of the therapeutically effective substances are needed -- such as proteins or nucleic acids, for example. Researchers in Germany are now presenting several processes with which biomolecules can be harvested quickly, robustly, reliably and with versatility.

Before a new medication arrives on the market, it must be tested on animal models and in humans. In order to conduct these tests, a substantial amount of the therapeutically effective substances are needed -- such as proteins or nucleic acids, for example. At the BIO International Convention 2010 in Chicago from May 3 to 6, Fraunhofer researchers will present several processes with which biomolecules can be harvested quickly, robustly, reliably and with versatility -- and all processes comply with the GMP standard.

Biomolecules are medicine's jacks-of-all-trades: They are suitable for the diagnosis and treatment of cancer diseases; they are used in the treatment of multiple sclerosis and asthma; they help stimulate the build-up of the body's own immune defenses with flu and polio inoculations. In the laboratories of the pharmaceutical industry, new biomolecules are constantly being engineered: Specific antibodies, customized proteins and nucleic acids -- the core components of genetic material -- are considered promising candidates for therapeutic approaches.

"Medical-pharmacological research will soon be using more biomolecules than ever before. Processes will be increasingly needed with which these biomolecules can be produced rapidly, in sufficient quantities and of clinically quality," says Dr. Holger Ziehr, who heads the pharmaceutical biotechnology department of the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM at its Braunschweig site. "Our new platform technologies meet these performance capabilities: We can synthesize nearly any antibody, protein or nucleic acid in cell cultures -- irrespective of their binding properties and base sequences." The systems for producing customized biomolecules meet the "Good Manufacturing Practice" -"GMP" -- quality standard of the European Medicines Agency EMA as well as the USA's Food and Drug Administration FDA.

For the production of the various classes of biomolecules, the researchers at ITEM are working closely with the Fraunhofer USA Center for Molecular Biotechnology CMB in Newark, Delaware. Three production systems in total are operated at both sites: In Braunschweig, there are bioreactors that produce antibodies in transgenic cells -- here they use CHO cells, the cells from hamster ovaries that are commonly deployed in cell research. In addition, the intestinal bacteria E. coli are used for harvesting any nucleic acids. The Delaware-based specialists are able to produce proteins or peptides in plants using "molecular farming." The plants for this are infected with a virus non-toxic to humans that contains the genetic template for the synthesis of the desired biomolecule.

"The Fraunhofer GMP platform technologies are not only extraordinarily versatile for this, they also help save a lot of time in the production and development of candidates for biopharmaceutical substances," explains Ziehr. "We can offer industry customers our full expertise -- from the production of tailored biomolecules to preclinical tests based on 'Good Laboratory Practice' -- 'GLP' -- through to clinical investigations per the GCP or 'Good Clinical Practice' standard. Outside of the major pharmaceutical corporations in Germany, there is nothing else like this except at the Fraunhofer-Group for Life Sciences."


Story Source:

The above story is based on materials provided by Fraunhofer-Gesellschaft. Note: Materials may be edited for content and length.


Cite This Page:

Fraunhofer-Gesellschaft. "New medications faster: Harvesting biomolecules more quickly and reliably." ScienceDaily. ScienceDaily, 11 April 2010. <www.sciencedaily.com/releases/2010/04/100408095502.htm>.
Fraunhofer-Gesellschaft. (2010, April 11). New medications faster: Harvesting biomolecules more quickly and reliably. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2010/04/100408095502.htm
Fraunhofer-Gesellschaft. "New medications faster: Harvesting biomolecules more quickly and reliably." ScienceDaily. www.sciencedaily.com/releases/2010/04/100408095502.htm (accessed July 25, 2014).

Share This




More Matter & Energy News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

TSA Administrator on Politics and Flight Bans

TSA Administrator on Politics and Flight Bans

AP (July 24, 2014) TSA administrator, John Pistole's took part in the Aspen Security Forum 2014, where he answered questions on lifting of the ban on flights into Israel's Tel Aviv airport and whether politics played a role in lifting the ban. (July 24) Video provided by AP
Powered by NewsLook.com
Creative Makeovers for Ugly Cellphone Towers

Creative Makeovers for Ugly Cellphone Towers

AP (July 24, 2014) Mobile phone companies and communities across the country are going to new lengths to disguise those unsightly cellphone towers. From a church bell tower to a flagpole, even a pencil, some towers are trying to make a point. (July 24) Video provided by AP
Powered by NewsLook.com
Algonquin Power Goes Activist on Its Target Gas Natural

Algonquin Power Goes Activist on Its Target Gas Natural

TheStreet (July 23, 2014) When The Deal's Amanda Levin exclusively reported that Gas Natural had been talking to potential suitors, the Ohio company responded with a flat denial, claiming its board had not talked to anyone about a possible sale. Lo and behold, Canadian utility Algonquin Power and Utilities not only had approached the company, but it did it three times. Its last offer was for $13 per share as Gas Natural's was trading at a 60-day moving average of about $12.50 per share. Now Algonquin, which has a 4.9% stake in Gas Natural, has taken its case to shareholders, calling on them to back its proposals or, possibly, a change in the target's board. Video provided by TheStreet
Powered by NewsLook.com
Robot Parking Valet Creates Stress-Free Travel

Robot Parking Valet Creates Stress-Free Travel

AP (July 23, 2014) 'Ray' the robotic parking valet at Dusseldorf Airport in Germany lets travelers to avoid the hassle of finding a parking spot before heading to the check-in desk. (July 23) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins